GET DAILY SIGNALSColgate-Palmolive (CL): +6.9% YTD Ahead of Q1 2026 Earnings
Key Takeaways
- Analysts expect Q1 2026 EPS of $0.95, a 4.4% increase from the year-ago quarter.
- Consensus revenue estimate stands at $5.20 billion, up 5.8% year-over-year from $4.91 billion.
- Organic sales growth is projected around 0.5%, within the company's full-year 2026 guidance of 1% to 4%.
- Investors will focus on gross margin trends and updates to emerging market performance.
- Stock has risen 6.9% year-to-date but declined 6.8% over the past year amid category pressures.
- Q4 2025 showed organic sales acceleration to 2.2%, setting a positive tone for 2026.
Earnings Context and Why It Matters
Colgate-Palmolive (CL), a global leader in oral, personal, and home care products, is heading into its pivotal Q1 2026 earnings report against a backdrop of ongoing challenges in the consumer staples sector. The company has shown resilience thanks to steady demand for essentials like toothpaste and pet nutrition, though recent quarters have been pressured by foreign exchange headwinds and category softness in developed markets. After delivering 2.2% organic sales growth in Q4 2025—up from 1.4% in Q1 2025—this upcoming release will indicate whether that momentum carries forward. From what I see, it's particularly important for investors tracking pricing power, innovation progress, and strength in emerging markets, which account for over half of sales. With shares around $84-85, these results could shape views on CL's long-term growth potential in today's high-interest-rate setting.
Earnings Expectations
Wall Street looks for adjusted EPS of $0.95 in the first quarter ended March 31, 2026, marking 4.4% growth from last year, supported by operational efficiencies and pricing actions. The revenue consensus sits at $5.20 billion, up 5.8% from Q1 2025's $4.91 billion, although FX impacts may moderate net sales growth. Analysts project organic sales growth at about 0.5%, fitting the lower end of FY2026 guidance (1%-4%). One thing that stands out is the focus on gross margins, where productivity gains should counter input cost inflation, along with updates from key divisions like North America and Latin America. CL has a track record of beating EPS estimates lately—Q4 2025 came in at $0.95, topping consensus by 4% and sparking a positive stock move. On average, the shares shift 3-5% post-earnings when organic growth beats expectations. I also checked CL against peers using Tickeron’s AI Screener, which highlighted its relative stability in the sector.
Market Reaction and Investor Sentiment
Heading into the May 1 release, CL shares have been flat to slightly lower, mirroring cautious investor sentiment amid broader market uncertainty and tariff worries. Average analyst price targets hover around $95, suggesting upside, though recent cuts from firms like Barclays point to near-term growth risks. In my view, weaker organic growth in North America or rising competition could weigh on results, while history shows the stock climbs on organic beats but falls on guidance misses—making management's commentary key during the 8:00 a.m. ET webcast.
Tools I Use: Tickeron’s AI Screener
In my analysis of consumer staples names like CL, Tickeron’s AI Screener stands out as a powerful AI-driven tool for discovering stocks and ETFs. It lets me filter thousands of assets using customizable criteria like technical patterns, fundamentals, trends, volatility, and AI signals—covering industry, market cap, indicators, price patterns, and performance metrics. This streamlines finding trade ideas, breakouts, and opportunities far better than manual scans. I use it regularly to sharpen my view on sector leaders.
Forward Outlook and Key Factors to Monitor
Post-Q1, keep an eye on tweaks to FY2026 guidance: 1%-4% organic sales growth and 2%-6% net sales expansion, factoring in FX and tariffs. Management might adjust based on Q1, especially emerging markets where growth has led developed ones. Divisional breakdowns matter—Latin America and Europe were strong in Q4 2025, while North America grapples with category issues. Gross margin progress, fueled by supply chain gains, will reveal pricing durability against raw material swings. Watch for the May 8 annual meeting, Q2 earnings, plus broader trends like consumer spending, new oral care launches, and pet nutrition recovery after private label shifts. Strong execution across categories could underscore CL's defensive qualities in staples.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
CL's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for CL turned positive on October 06, 2026. Looking at past instances where CL's MACD turned positive, the stock continued to rise in 25 of 43 cases over the following month. The odds of a continued upward trend are 58%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 29, 2026. You may want to consider a long position or call options on CL as a result. In 35 of 68 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 51%.
CL moved above its 50-day moving average on October 12, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for CL crossed bullishly above the 50-day moving average on October 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 50%.
Following a +4.58% 3-day Advance, the price is estimated to grow further. Considering data from situations where CL advanced for three days, in 145 of 314 cases, the price rose further within the following month. The odds of a continued upward trend are 46%.
The Aroon Indicator entered an Uptrend today. In 118 of 277 cases where CL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 43%.
Bearish Trend Analysis
The 10-day RSI Indicator for CL moved out of overbought territory on October 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 similar instances where the indicator moved out of overbought territory. In 12 of the 38 cases, the stock moved lower in the following days. This puts the odds of a move lower at 32%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 47%.
CL broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 8 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 19 (best 1 - 100 worst), indicating outstanding price growth. CL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 45 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock slightly better than average.
The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CL's P/B Ratio (329.104) is very high in comparison to the industry average of (21.014). P/E Ratio (38.358) is within average values for comparable stocks, (16.476). Projected Growth (PEG Ratio) (1.577) is also within normal values, averaging (1.518). Dividend Yield (0.022) settles around the average of (0.033) among similar stocks. P/S Ratio (3.331) is also within normal values, averaging (1.902).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a maker of oral, personal, and household products
Industry HouseholdPersonalCare
Advertisement